ELZEGURAN
UNII 5DBG4GC6MX
Substance Identification & Data
This profile provides standardized clinical and technical data for Elzeguran, uniquely identified by the FDA Unique Ingredient Identifier (UNII) 5DBG4GC6MX.
Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2724283-08-1 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.
5DBG4GC6MX
2724283-08-1
N/A
Detailed Substance Profile
Preferred Name
ELZEGURAN
Official standardized name for this substance within the FDA UNII nomenclature system.
INN ID
14150
Sequential identifier assigned via the WHO International Nonproprietary Name program.
Substance Type
Elzeguran
ISO 11238 classification category (e.g., Chemical, Polymer, Protein).
Synonyms and Nomenclature
This section provides a complete list of nomenclature and identifier mappings for Elzeguran. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.
FDA Official Name
Elzeguran
Common Names & Synonyms
RNA (human/Macaca fascicularis proprotein convertase subtilisin kexin 9 gene PCSK9-targeting guide RNA PCS-gRNA009)
elzeguran [INN]
guide RNA (gRNA) targeting a splice donor site at the junction of exon 1 and intron 1 of the human proprotein convertase subtilisin/kexin type 9 (PCSK9) gene. all-P-ambo-2′-O-methyl-P-thiocytidylyl-(3′→5′)-2′-Omethyl-P-thiocytidylyl-(3′→5′)-2′-O-methyl-Pthiocytidylyl-( 3′→5′)-guanylyl-(3′→5′)-cytidylyl-(3′→5′)-adenylyl-(3′→5′)-cytidylyl-(3′→5′)-cytidylyl-(3′→5′)-uridylyl-(3′→5′)-uridylyl-(3′→5′)-guanylyl-(3′→5′)-guanylyl-(3′→5′)-cytidylyl-(3′→5′)-guanylyl-(3′→5′)-cytidylyl-(3′→5′)-adenylyl-(3′→5′)-guanylyl-(3′→5′)-cytidylyl-(3′→5′)-guanylyl-(3′→5′)-guanylyl-(3′→5′)-2′-O-methylguanylyl-(3′→5′)-uridylyl-(3′→5′)-uridylyl-(3′→5′)-uridylyl-(3′→5′)-uridylyl-(3′→5′)-adenylyl-(3′→5′)-guanylyl-(3′→5′)-2′-O-methyladenylyl-(3′→5′)-2′-O-methylguanylyl-(3′→5′)-2′-O-methylcytidylyl-(3′→5′)-2′-O-methyluridylyl-(3′→5′)-2′-Omethyladenylyl-( 3′→5′)-guanylyl-(3′→5′)-2′-Omethyladenylyl-( 3′→5′)-2′-O-methyladenylyl-(3′→5′)-2′-O-methyladenylyl-(3′→5′)-2′-O-methyluridylyl-(3′→5′)-2′-O-methyladenylyl-(3′→5′)-2′-O-methylguanylyl-(3′→5′)-2′-O-methylcytidylyl-(3′→5′)-2′-Omethyladenylyl-( 3′→5′)-2′-O-methyladenylyl-(3′→5′)-guanylyl-(3′→5′)-uridylyl-(3′→5′)-uridylyl-(3′→5′)-2′-Omethyladenylyl-( 3′→5′)-adenylyl-(3′→5′)-2′-Omethyladenylyl-( 3′→5′)-adenylyl-(3′→5′)-2′-Omethyluridylyl-( 3′→5′)-adenylyl-(3′→5′)-2′-Omethyladenylyl-( 3′→5′)-2′-O-methylguanylyl-(3′→5′)-2′-O-methylguanylyl-(3′→5′)-2′-O-methylcytidylyl-(3′→5′)-2′-O-methyluridylyl-(3′→5′)-2′-O-methyladenylyl-(3′→5′)-guanylyl-(3′→5′)-uridylyl-(3′→5′)-2′-Omethylcytidylyl-( 3′→5′)-2′-O-methylcytidylyl-(3′→5′)-guanylyl-(3′→5′)-uridylyl-(3′→5′)-uridylyl-(3′→5′)-adenylyl-(3′→5′)-2′-O-methyluridylyl-(3′→5′)-2′-Omethylcytidylyl-( 3′→5′)-adenylyl-(3′→5′)-adenylyl-(3′→5′)-2′-O-methylcytidylyl-(3′→5′)-2′-Omethyluridylyl-( 3′→5′)-2′-O-methyluridylyl-(3′→5′)-guanylyl-(3′→5′)-2′-O-methyladenylyl-(3′→5′)-2′-Omethyladenylyl-( 3′→5′)-2′-O-methyladenylyl-(3′→5′)-2′-O-methyladenylyl-(3′→5′)-2′-O-methyladenylyl-(3′→5′)-2′-O-methylguanylyl-(3′→5′)-2′-O-methyluridylyl-(3′→5′)-2′-O-methylguanylyl-(3′→5′)-guanylyl-(3′→5′)-2′-O-methylcytidylyl-(3′→5′)-2′-O-methyladenylyl-(3′→5′)-2′-O-methylcytidylyl-(3′→5′)-2′-Omethylcytidylyl-( 3′→5′)-2′-O-methylguanylyl-(3′→5′)-2′-O-methyladenylyl-(3′→5′)-2′-O-methylguanylyl-(3′→5′)-2′-O-methyluridylyl-(3′→5′)-2′-O-methylcytidylyl-(3′→5′)-2′-O-methylguanylyl-(3′→5′)-2′-Omethylguanylyl-( 3′→5′)-2′-O-methyluridylyl-(3′→5′)-2′-O-methylguanylyl-(3′→5′)-2′-O-methylcytidylyl-(3′→5′)-2′-O-methyl-P-thiouridylyl-(3′→5′)-2′-O-methyl-Pthiouridylyl-( 3′→5′)-2′-O-methyl-P-thiouridylyl-(3′→5′)-2′-O-methyluridine
